Januvia (sitagliptin) is an oral prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. It belongs to a class called DPP-4 inhibitors and is taken once daily. Januvia is not approved for type 1 diabetes or diabetic ketoacidosis.
How Januvia Works
Januvia blocks an enzyme called dipeptidyl peptidase-4 (DPP-4). DPP-4 normally breaks down incretin hormones — GLP-1 and GIP — that help the pancreas release insulin after meals. By blocking DPP-4, Januvia raises incretin levels, which increases insulin release when blood sugar is high and decreases the amount of glucose released by the liver.
Unlike sulfonylureas, Januvia only stimulates insulin when glucose is elevated, which is why it rarely causes hypoglycemia on its own. It is a useful option for adults who cannot take metformin or need a second agent added to their regimen. For broader context on medication options, see our prediabetes and type 2 diabetes treatment guide.
Who Januvia Is Prescribed For
The FDA has approved Januvia as an add-on to diet and exercise in adults with type 2 diabetes. It may be used as monotherapy when metformin is not tolerated, or in combination with metformin, sulfonylureas, thiazolidinediones (such as pioglitazone), or insulin. It is not a first-line choice for most adults — the American Diabetes Association still recommends metformin or a GLP-1 receptor agonist as initial pharmacotherapy for most newly diagnosed cases.
Dosing and How to Take It
The standard dose of Januvia is 100 mg taken by mouth once daily, with or without food. Dosing adjustments depend on kidney function, which is measured using estimated glomerular filtration rate (eGFR).
| Kidney Function (eGFR) | Recommended Januvia Dose |
|---|---|
| 45 or above (normal to mild impairment) | 100 mg once daily |
| 30 to under 45 (moderate impairment) | 50 mg once daily |
| Under 30 or on dialysis | 25 mg once daily |
If you miss a dose, take it as soon as you remember unless it is almost time for the next one. Never double up to catch up. Kidney function should be checked before starting Januvia and at least once a year during treatment.
How Well Januvia Lowers A1C
According to the FDA prescribing information and multiple randomized clinical trials, Januvia lowers A1C by approximately 0.5 to 0.8 percentage points when used alone or added to metformin. The effect is smaller than what is typically seen with GLP-1 receptor agonists or SGLT2 inhibitors but comparable to other DPP-4 inhibitors such as linagliptin and saxagliptin. People with higher baseline A1C tend to see larger reductions.
Understanding your starting A1C matters when setting expectations. Review our A1C levels guide to see where your number fits on the diabetes spectrum and what a realistic treatment target looks like.
Common Side Effects
Most people tolerate Januvia well. In clinical trials the most frequent side effects reported more often than with placebo were:
- Upper respiratory tract infection
- Stuffy or runny nose and sore throat (nasopharyngitis)
- Headache
- Mild stomach discomfort
These symptoms are usually mild and do not require stopping the medication. Tell your doctor if they persist or worsen.
Serious Warnings and Risks
The FDA label for Januvia includes several important warnings based on post-marketing reports and trial data.
Pancreatitis
Acute pancreatitis, including rare fatal and hemorrhagic cases, has been reported in people taking sitagliptin. Stop Januvia and contact your doctor immediately if you develop severe abdominal pain that radiates to the back, with or without vomiting. People with a history of pancreatitis should discuss alternative therapies with their prescriber.
Severe Joint Pain
The FDA has warned that DPP-4 inhibitors, including Januvia, can cause severe and sometimes disabling joint pain. Symptoms may start days to years after beginning treatment and typically resolve when the drug is stopped. If you develop new or worsening joint pain, contact your doctor.
Heart Failure
Although large cardiovascular outcome trials (TECOS) did not show increased heart failure hospitalization with sitagliptin specifically, other drugs in this class have. People with a history of heart failure should be monitored carefully.
Hypersensitivity Reactions
Serious allergic reactions including anaphylaxis, angioedema, and skin conditions such as Stevens-Johnson syndrome have occurred. Stop Januvia and seek emergency care for swelling of the face, lips, tongue, or throat, difficulty breathing, or a widespread rash.
Bullous Pemphigoid
This blistering skin condition has been reported with DPP-4 inhibitors. It usually requires stopping the drug and treating with topical or systemic corticosteroids.
Drug Interactions and Precautions
Januvia has relatively few drug interactions because it is primarily eliminated by the kidneys unchanged. The most important consideration is combination with other blood sugar-lowering medications. When Januvia is added to insulin or a sulfonylurea, the risk of hypoglycemia rises, and the dose of the companion drug may need to be reduced.
Tell your doctor about all prescription drugs, over-the-counter medicines, supplements, and herbal products you take. Drink alcohol only in moderation, as excessive intake can worsen blood sugar control and raise the risk of pancreatitis.
Januvia vs. Other Type 2 Diabetes Medications
Choosing among oral agents depends on your A1C, kidney function, weight goals, cardiovascular risk, and cost. The table below summarizes how Januvia compares to other widely used options.
| Medication Class | Example | Typical A1C Reduction | Weight Effect | Hypoglycemia Risk (alone) |
|---|---|---|---|---|
| DPP-4 inhibitor | Januvia (sitagliptin) | 0.5 to 0.8% | Neutral | Low |
| Biguanide | Metformin | 1.0 to 1.5% | Neutral to slight loss | Low |
| SGLT2 inhibitor | Jardiance, Farxiga | 0.7 to 1.0% | Loss | Low |
| GLP-1 receptor agonist | Ozempic, Trulicity | 1.0 to 1.8% | Loss | Low |
| Sulfonylurea | Glipizide, glimepiride | 1.0 to 1.5% | Gain | Moderate to high |
Januvia is often chosen when metformin is not enough, weight is a concern, and cost or tolerance rules out a GLP-1. A generic version, sitagliptin generic, became available in the United States in 2022, making it more affordable for many patients.
Cost and Insurance Coverage
Brand-name Januvia has historically been one of the more expensive oral diabetes drugs, with cash prices running several hundred dollars per month. Since generic sitagliptin became available, prices have fallen. Most commercial insurance plans and Medicare Part D formularies now cover either the brand or generic form with tiered copays. Manufacturer savings cards and patient assistance programs from Merck may reduce out-of-pocket cost for eligible patients.
What to Monitor While Taking Januvia
Regular follow-up is the backbone of safe therapy. Your care team will usually check:
- A1C every 3 months until at goal, then every 6 months
- Fasting glucose or home monitoring as advised
- Kidney function (eGFR and creatinine) at baseline and at least annually
- Liver enzymes if symptoms develop
- Symptoms of pancreatitis, joint pain, or allergic reactions at every visit
Lifestyle Still Matters
Januvia works best when combined with the same lifestyle changes that define prediabetes and type 2 diabetes care: a balanced eating pattern, 150 minutes of moderate activity per week, 7 percent body weight loss if overweight, and not smoking. Medication adds to these efforts — it does not replace them. The ADA estimates that structured lifestyle programs can reduce progression from prediabetes to type 2 diabetes by roughly 58 percent in adults at high risk.
When to Call Your Doctor
Contact your prescriber promptly if you experience any of the following while taking Januvia:
- Severe or persistent abdominal pain
- Nausea and vomiting that will not stop
- New or worsening joint pain
- Signs of low blood sugar (shakiness, sweating, confusion) if you also take insulin or a sulfonylurea
- Yellowing of skin or eyes
- Skin blistering or widespread rash
- Swelling of face, lips, or throat, or trouble breathing
The Bottom Line
Januvia is a well-tolerated once-daily oral medication that modestly lowers A1C in adults with type 2 diabetes. It is weight-neutral, carries low hypoglycemia risk when used alone, and is safe across most kidney function ranges with dose adjustment. It is not the most potent option, and rare but serious risks like pancreatitis and severe joint pain deserve attention. Work with your clinician to decide whether Januvia — or the newer generic sitagliptin — fits your treatment plan alongside the diet, activity, and weight goals that remain the foundation of diabetes care.
